Table 1.
Analysis of Genotype and Allele frequencies of the BAT1 -22, TNFA -308 and TNFA -850 polymorphisms
| Marker | Genotype or allele | Ctrl numbers (%) | AD numbers (%) |
| BAT1 -22 | 1/1 | 144 (40.1) | 117 (43.0) |
| 1/2 | 167 (46.5) | 138 (50.7) | |
| 2/2 | 48 (13.4) | 17 (6.3)a | |
| 1 | 455 (63.4) | 372 (68.4) | |
| 2 | 263 (36.6) | 172 (31.6) | |
| TNFA -308 | 1/1 | 226 (63.0) | 188 (69.1) |
| 1/2 | 104 (29.0) | 70 (25.7) | |
| 2/2 | 29 (8.0) | 14 (5.1) | |
| 1 | 556 (77.4) | 446 (82.0) | |
| 2 | 162 (22.6) | 98 (18.0)b | |
| TNFA -850 | 1/1 | 287 (79.9) | 183 (67.3) |
| 1/2 | 61 (17.0) | 70 (25.7) | |
| 2/2 | 11 (3.1) | 19 (7.0)c | |
| 1 | 635 (88.4) | 436 (80.1) | |
| 2 | 83 (11.6) | 108 (19.9)d |
Ctrl = Control cases without AD pathology
AD = Alzheimer's disease cases
a BAT1 -22*2/2 versus non-2/2 in AD, P < .005 (Pearson χ2 = 8.49) OR = 0.43 (95% CI = 0.24 – 0.77).
b TNFA -308*2 allele in AD, P = .048 (Pearson χ2 = 3.91) OR = 0.75 (95% CI = 0.57 – 1.00).
c TNFA -850*(2/2, 1/2) versus 1/1 in AD, P < .001 (Pearson χ2 = 13.06) OR = 1.94 (95% CI = 1.35 – 2.78.0).
d TNFA -850*2 allele in AD, P < .001 (Pearson χ2 = 16.57) OR = 1.90 (95% CI = 1.39 – 2.59).